文献速递眼底病与葡萄膜炎

地塞米松植入剂治疗非感染性葡萄膜炎的成本效益分析

Dexamethasone implant for non-infectious uveitis: is it cost-effective?
PubMed 文献 · Br J Ophthalmol · 2019-02-11

本研究采用Markov模型评估地塞米松植入剂联合当前实践(免疫抑制剂和全身糖皮质激素)对比单用当前实践治疗非感染性中间型、后型或全葡萄膜炎的成本效益。结论认为按英国常用阈值地塞米松具有成本效益,但证据稀缺导致结果存在较大不确定性。

要点

  • 对结果影响最大的因素为失明率和地塞米松避免失明的相对比例。

核心结论

  • 按英国通用阈值,地塞米松植入剂联合当前实践对比单用当前实践治疗非感染性中间型、后型或全葡萄膜炎估计具有成本效益。

研究设计与样本

  • 构建Markov模型估算地塞米松植入剂的成本与收益。
  • 通过系统综述识别相关可用证据。
  • 使用关键随机对照试验HURON的生活质量数据估算干预效果,对照为安慰剂加有限当前实践(LCP)。
  • 分析采用英国国家卫生服务(NHS)和个人社会服务视角,成本基于英国标准来源计算。

主要发现

  • 对结果影响最大的因素为失明率和地塞米松避免失明的相对比例。

临床怎么用

  • 在非感染性中间型、后型或全葡萄膜炎患者中,地塞米松植入剂联合当前实践可能具有成本效益。
  • 临床决策需考虑证据不确定性,关注失明率及地塞米松避免失明的效果对成本效益的影响。

局限性

  • 证据稀缺导致结果存在较大不确定性。
  • 未来需研究地塞米松对比当前实践(而非LCP)的效果、单侧与双侧葡萄膜炎亚组分析、长期失明发生率及地塞米松避免失明的效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Uveitis is inflammation inside the eye. The objective of this study is to assess the cost-effectiveness of a dexamethasone implant plus current practice (immunosuppressants and systemic corticosteroids) compared with current practice alone, in patients with non-infectious intermediate, posterior or pan-uveitis and to identify areas for future research. METHODS: A Markov model was built to estimate the costs and benefits of dexamethasone. Systematic reviews were performed to identify available relevant evidence. Quality of life data from the key randomised-controlled trial (HURON) was used to estimate the interventions' effectiveness compared with the trial's comparator arm (placebo plus limited current practice (LCP)). The analysis took a National Health Service and Personal Social Services perspective. Costs were calculated based on standard UK sources. RESULTS: The incremental cost-effectiveness ratio (ICER) of one dexamethasone implant compared with LCP is estimated as £19 509 per quality-adjusted life year (QALY) gained. The factors with the largest impact on the results were rate of blindness and relative proportion of blindness cases avoided by dexamethasone. Using plausible alternative assumptions, dexamethasone could be cost saving or it may be associated with an ICER of £56 329 per QALY gained compared with LCP. CONCLUSIONS: Dexamethasone is estimated to be cost-effective using generally accepted UK thresholds. However, there is substantial uncertainty around these results due to scarcity of evidence. Future research on the following would help provide more reliable estimates: effectiveness of dexamethasone versus current practice (instead of LCP), with subgroup analyses for unilateral and bilateral uveitis, incidence of long-term blindness and effectiveness of dexamethasone in avoiding blindness.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Squires H, Bermejo I, Poku EN, et al. Dexamethasone implant for non-infectious uveitis: is it cost-effective? Br J Ophthalmol. 2019. PMID: 30745307. doi:10.1136/bjophthalmol-2018-312765

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。